Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclosporin for polymyositis

K Bendtzen, N Tvede, V Andersen

    Lancet (London, England)
    |April 7, 1984
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Genetic polymorphisms of dsRNA ligating pattern recognition receptors TLR3, MDA5, and RIG-I. Association with systemic lupus erythematosus and clinical phenotypes.

    Rheumatology international·2014
    Same author

    Cytokines and soluble IL-4 in patients with acute optic neuritis and multiple sclerosis.

    European journal of neurology·2013
    Same author

    Commentary: antibodies reacting with the infliximab Fab portion--something new? Authors' reply.

    Alimentary pharmacology & therapeutics·2013
    Same author

    Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease.

    Alimentary pharmacology & therapeutics·2013
    Same author

    Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD.

    Alimentary pharmacology & therapeutics·2012
    Same author

    Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease.

    Alimentary pharmacology & therapeutics·2012